New ultrasound score may sharpen risk prediction for PAH patients

NCT ID NCT07266012

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at whether a new ultrasound score called VExUS can help doctors better assess risk in people with pulmonary arterial hypertension (PAH). Researchers measured VExUS in 86 adults and compared it to standard tests like heart catheterization and blood markers. The goal was to see if VExUS could spot early signs of fluid buildup and improve current risk models.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a better, non-invasive way to assess risk and congestion in PAH patients, potentially improving monitoring and treatment decisions.

What could go wrong

This is an observational study, not a treatment trial. The VExUS score may not prove useful enough to change current practice, and results may not apply to all PAH patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hyperemia pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Istanbul University-Cerrahpasa Institute of Cardiology

    Istanbul, FATIH, 34098, Turkey (Türkiye)